The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1210
Entecavir (Baraclude) for Chronic Hepatitis B
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Entecavir (Baraclude – Bristol-Myers Squibb), a nucleoside analog, has been approved by the FDA for treatment of adults with active chronic hepatitis B virus (HBV) infection.

DRUGS FOR HEPATITIS B — Chronic HBV infection is currently treated with interferon alfa, lamivudine or adefovir.1 Lamivudine is much better tolerated than interferon and much less expensive, but resistance to the drug occurs in about 15%-30% of patients after one year and in about 50% after 3 years.2 Resistance has been less of a problem with adefovir, which is active against lamivudine-resistant strains, but can cause nephrotoxicity.3

CLINICAL STUDIES — FDA approval was based on 3 unpublished randomized, double-blind trials (described in the package insert) comparing treatment with entecavir to lamivudine in adults with chronic HBV. Some ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Entecavir (Baraclude) for Chronic Hepatitis B
Article code: 1210c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian